Therefore, we considered, combining with a biological delivery system that targets hypoxic areas of the tumor, the KCNJ2 inhibitors would exhibit more effective for anti-OS and evade nonspecific toxicity to other tissues. Here, KCNJ2 is linked to neoplasm.